@article {Dombret510, author = {Marie-Christine Dombret and Khuder Alagha and Louis Philippe Boulet and Pierre Yves Brillet and Guy Joos and Michel Laviolette and Renaud Louis and Thierry Rochat and Paola Soccal and Michel Aubier and Pascal Chanez}, title = {Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults}, volume = {23}, number = {134}, pages = {510--518}, year = {2014}, doi = {10.1183/09059180.00005114}, publisher = {European Respiratory Society}, abstract = {Bronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following the treatment. It is an innovative treatment whose clinical efficacy and safety are beginning to be better understood. Since this is a device-based therapy, the overall evaluation of risk{\textendash}benefit is unlike that of pharmaceutical products; safety aspects, regulatory requirements, study design and effect size assessment may be unfamiliar. The mechanisms of action and optimal patient selection need to be addressed in further rigorous clinical and scientific studies. Bronchial thermoplasty fits in perfectly with the movement to expand personalised medicine in the field of chronic airway disorders. This is a device-based complimentary asthma treatment that must be supported and developed in order to meet the unmet needs of modern severe asthma management. The mechanisms of action and the type of patients that benefit from bronchial thermoplasty are the most important challenges for bronchial thermoplasty in the future.}, issn = {0905-9180}, URL = {https://err.ersjournals.com/content/23/134/510}, eprint = {https://err.ersjournals.com/content/23/134/510.full.pdf}, journal = {European Respiratory Review} }